title: Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
abstract: Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of major histocompatability complex II (MHC-II) that may lead to immune evasion. Here, we prepared pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic T lymphocytes (CTLs), promote Th1-type cell-mediated secretion of cytokines IFN-γ and IL-2 while inhibiting Th2-type cell-mediated secretion of IL-4, and inhibit the secretion of TGF-β. Generally, the epigenetically modified vaccine could enhance the body's antitumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.
authors.affiliation: Organ Transplantation Center, Department of General Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Yifeng
authors.initials: Y
authors.lastname: Tao
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Junjie
authors.initials: J
authors.lastname: Xie
authors.forename: Chuan
authors.initials: C
authors.lastname: Shen
authors.forename: Zhecheng
authors.initials: Z
authors.lastname: Zhu
mesh_terms: D000818:Animals; D000941:Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018920:Coculture Techniques; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic; D019175:DNA Methylation; D004195:Disease Models, Animal; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D009687:Nuclear Proteins / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D037182:T-Cell Antigen Receptor Specificity; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D015534:Trans-Activators / Q000235:genetics; D023041:Xenograft Model Antitumor Assays
chemical_list: D000941:Antigens; D019496:Cancer Vaccines; D016207:Cytokines; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D015534:Trans-Activators